Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07560306 · ClinicalTrials.gov registry record · Phase 3
[64Cu]FBP8 PET for Early Detection of Intracardiac Thrombus in Amyloid Cardiomyopathy
A Phase 3 study, sponsored by Brigham and Women's Hospital.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 20
- Enrollment target
NCT07560306 is a Phase 3 study that is actively recruiting participants, run by Brigham and Women's Hospital. The registered enrollment target is 20 participants.
The verdict
NCT07560306, a Phase 3 study, is actively recruiting participants, sponsored by Brigham and Women's Hospital.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 20 participants
- Enrollment target
Study Summary
The primary goal of this pilot study is to determine whether \[64Cu\]FBP8, a novel fibrin-binding positron emission tomography (PET) probe, can identify intracardiac thrombi when paired with simultaneous hybrid cardiac PET/MRI in twenty (20) individuals with transthyretin or light chain cardiac amyloidosis and atrial fibrillation (AF) or atrial flutter (AF). The primary hypothesis of this study is that \[64Cu\]FBP8 PET/MRI can identify intracardiac thrombi in \>90% of subjects with confirmed intracardiac thrombi based on transesophageal echocardiogram (TEE). In secondary analyses, the investigators will seek to determine associations between intracardiac thrombi and left atrial function and left ventricular amyloid burden.
Interventions
- DRUG [64Cu]FBP8 PET/MR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-05-01 |
| Est. Completion | 2027-03-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07560306
The ClinicalTrials.gov registry entry for NCT07560306 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [64Cu]FBP8 PET/MR is the first listed.
NCT07560306 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07560306 about?
NCT07560306 is a clinical study titled "[64Cu]FBP8 PET for Early Detection of Intracardiac Thrombus in Amyloid Cardiomyopathy". The primary goal of this pilot study is to determine whether \[64Cu\]FBP8, a novel fibrin-binding positron emission tomography (PET) probe, can identify intracardiac thrombi when paired with simultaneous hybrid cardiac PET/MRI in twenty (20) individuals with transthyretin or light chain cardiac amyl...
What is the current status of trial NCT07560306?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 20 participants. The study started on 2026-05-01. Estimated completion is 2027-03-30.
What interventions are being tested in trial NCT07560306?
The interventions under investigation include: [64Cu]FBP8 PET/MR (DRUG).
Who is sponsoring clinical trial NCT07560306?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.